author-photo

Monika Garas

Hoffmann-La Roche

4

Papers

14

Citations

Citation Trend

Filter By

Papers (2) Sort By

Journal Conference Others

Annualized Relapse Rate and Confirmed Disability Progression in Patients Receiving Continuous Ocrelizumab or Switching From Interferon Beta-1a to Ocrelizumab Therapy in the Open-Label Extension Period of the Phase III Trials of Ocrelizumab in Patients With Relapsing Multiple Sclerosis (P1.366)

2018 Neurology
Show All
- Source
- Cite
- Save
Citations (3)
Sustained Reduction in Confirmed Disability Progression in Patients with Primary Progressive Multiple Sclerosis Treated with Ocrelizumab in the Open-label Extension Period of the Phase III ORATORIO trial

2018 Multiple sclerosis and related disorders
Show All
- Source
- Cite
- Save
Citations (2)